| Literature DB >> 33330754 |
Shinichi Oka1, Mikiko Ogata1, Misao Takano1, Ryogo Minamimoto2, Masatoshi Hotta2, Tsuyoshi Tajima3, Naoyoshi Nagata4,5, Kunihisa Tsukada1, Katsuji Teruya1, Yoshimi Kikuchi1, Hiroyuki Gatanaga1.
Abstract
Along improvement of prognosis of HIV-1-infected patients due to successful anti-retroviral therapy, main causes of death in the patients have been changing from AIDS to non-AIDS defining malignancies (NADM) recently. However, little is known about the prevalence and incidence of NADM in patients, and especially in HIV-1-infected hemophiliacs. We prospectively conducted NADM screening with FDG-PET, chest CT, upper gastrointestinal endoscopy, tumor markers, and stool occult blood in hemophiliacs with a mean age of 48.9 years. Screening was done twice from December 2016 through March 2019; the first screening was used to calculate prevalence in 69 patients and the second was used to calculate incidence in 56 patients. The first screening revealed 4 cases of malignancies; three were cases of thyroid cancer and one was a case of a neuroendocrine tumor in the pancreas; prevalence was 5.8% (95% CI: 0.2-11.4%). During a mean follow-up of 1.2 years with 68.2 person-years (PYs), cancer was diagnosed in 2 cases (pancreatic and liver cancer) during the second screening. Incidence was 2.99/100 PY. It can be speculated that there might be around 40 cases of undiagnosed NADM currently and 20 cases of new NADM annually in this population, because 718 HIV-1-infected hemophiliacs are surviving in Japan according to the 2018 Nationwide Survey on Coagulation Disorders. Screening for NADM in HIV-1-infected hemophiliacs at other hospitals is strongly recommended. 2019, National Center for Global Health and Medicine.Entities:
Keywords: Cancer; incidence; prevalence; screening
Year: 2019 PMID: 33330754 PMCID: PMC7731093 DOI: 10.35772/ghm.2019.01015
Source DB: PubMed Journal: Glob Health Med ISSN: 2434-9186